


Future Lab Content Hub – COVID-19 R&D



Future Lab is a forward-thinking content hub that connects with readers in a targeted and interactive format. By aggregating relevant content into an informational portal, Future Lab helps scientists keep up with the latest technological advances and the newest discoveries.

This Future Lab is being designed for scientists involved in COVID-19 related research, diagnostic development, and therapeutic discovery and manufacturing.

Sponsorship benefits include thought leadership, branding, lead generation, and contextual editorial placement.

Sponsors Receive:

- ✓ Leads generated by gated content downloads
 - Leads derived from Biocompare gated content are shared between sub-topic sponsors
 - Leads generated by gated sponsored content are exclusive to that sponsor
 - Complete contact details are included
- ✓ Dedicated Sponsor Showcase Page
 - All of your content easily accessible from one location, accessible throughout the Future Lab
 - Helps establish thought leadership
- ✓ Detailed, monthly reporting to demonstrate ROI

Sponsorships are available for each of the sub-topics below. A total of six sponsorship slots are available.

- Research
- Diagnostics (including Test Kits)
- Therapeutics (including Vaccine Development)

Sponsorship is 6 months in duration and includes:

- Prominent sponsor branding throughout platform and one creative used to promote sponsor content
- Lead generation from the following sources:
 - Launch registration
 - Gated content downloads
- Contextual content placement
 - One 'sponsored content' placement slot per month per sub-topic sponsored
 - Selective gating of content for high-funnel lead generation purposes
- One product highlight per sub-topic sponsored

Biocompare's extensive, targeted multi-channel marketing program ensures all content is disseminated to the right audience using all of our available channels to drive engagement and content downloads.

Sponsorship pricing: 1 sub-topic: \$5,000; 2 sub-topics: \$9,000; 3 sub-topics: \$12,500

Future Lab Content Scope

Research

Here we will examine the latest findings on biological processes, virulence factors, COVID-19 pathways, and more as well as the use of sophisticated technologies to optimize analyses.

Diagnostics (including Test Kits)

The availability of accurate, easy-to-use, and scalable tests is essential to controlling the spread of COVID-19. This section will look at what's available now, innovative tests that could allow for more rapid testing, as well as the latest thinking around immunity and the challenges of contact tracking.

Therapeutics (including Vaccine Development)

Scientists are working around the clock to expedite the discovery and development of new therapies and vaccines. Articles in this section will focus on repurposing existing drugs as well as innovative therapeutics, and also manufacturing challenges.

Biocompare articles that may included:

Research

- *The molecular targets of SARS-CoV-2.*
- *T cells and their effect on COVID disease pathology.*
- *Use of whole genome sequencing to track transmission and spread of SARS-Co-V-2.*

Diagnostics (including Test Kits)

- *The latest in COVID-19 testing.* This article will review the availability, ease-of use, speed, and accuracy of existing tests.
- *Antibody tests.* A lot is riding on whether people have developed an antibody response to SARS-CoV-2. This article will look at recent research into immunity as well as the usefulness of antibody tests currently available.
- *CRISPR-based diagnostics.* Some researchers believe that CRISPR-based technology will be the next-generation of tests to diagnose COVID-19.

Therapeutics (including Vaccine Development)

- *Adaptive immune response.* A better understanding of the adaptive immune response is necessary for successful vaccine and therapeutic development.
- *Drug repurposing.* Many research groups are evaluating FDA approved drugs against SARS-CoV-2. This article will review some of the efforts and findings and next steps.
- *Scaling up manufacturing of vaccines.* Once a vaccine is approved, safe and rapid scale up will be essential. This article will review efforts being made now to prepare for eventual manufacturing scale up for approved vaccines.